ARIAD Pharma (ARIA) Shares Continue Lower as Feuerstein Piece Highlighted
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Ariad Pharma (Nasdaq: ARIA) is reacting negatively to a week-old article on drug pricing issues posted by former Presidential candidate Bernie Sanders. Notably, biotech watcher Adam Feuerstein penned an article on the topic the prior day (Oct. 6th), specifically targeting Ariad in the piece.
With the report, Feuerstein noted that Ariad hiked the price of its leukemia drug Iclusig four times this year, with the latest being an 8 percent price hike.
Again, for the complete story, click here. Shares of Ariad are down nearly 13 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Comstock Holding (CHCI) Surges 50%; Reason Unknown
- Globus Maritime (GLBS) Halted on LUDP
- Stocks with call price movement; MU TWTR
Create E-mail Alert Related CategoriesInsiders' Blog, Momentum Movers, Trader Talk
Related EntitiesAdam Feuerstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!